
    
      Locally advanced breast cancer is a common condition in development countries. Neoadjuvant
      chemotherapy gives the opportunity to identify genetic signatures associated with objective
      clinical and pathological complete responses.

      Patients will receive doxorubicin/cyclophosphamide with paclitaxel. Tumor samples collected
      before and after chemotherapy will be analyzed.
    
  